Medical devices, healthcare technology and the business of care
PMA approval · P250024

Trilogy Transcatheter Heart Valve System

JenaValve Technology, Inc. · Decision date Mar 17, 2026

MEDTECHLEDGER EXPLANATIONP250024

What did the FDA approve?

The FDA approved the Trilogy Transcatheter Heart Valve System from JenaValve Technology, Inc. for treating symptomatic, severe native tricuspid aortic valve regurgitation. The approval excludes cases caused by acute endocarditis, rheumatic heart disease, or acute aortic dissection.

Eligibility requires a Heart Team, including a cardiac surgeon, to judge the patient at high or greater risk for surgical aortic valve replacement. That judgment uses a predicted 30-day surgical mortality of 8% or higher based on the Society of Thoracic Surgeons risk score and other clinical co-morbidities not measured by the STS risk calculator.

FDA approval order statement

The Trilogy Transcatheter Heart Valve System is indicated for the treatment of symptomatic, severe native tricuspid aortic valve regurgitation (not due to acute endocarditis, rheumatic heart disease, or acute aortic dissection) in patients who are judged by a Heart Team, including a cardiac surgeon, to be at high or greater risk for surgical aortic valve replacement (i.e., predicted risk of surgical mortality >=8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Mar 17, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250024
Regulatory pathway
Premarket approval application
Product code
NPT
Decision code
APPR
Decision date
Mar 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250024 received

    Application receipt date recorded by FDA.

  2. P250024 · FDA decision

    APPR

  3. P250024/S006 · Related supplement

    Trilogy Transcatheter Heart Valve System

  4. P250024/S005 · Related supplement

    Trilogy Transcatheter Heart Valve System

Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250024

Product / regulatory recordCompanyPathwayDecision dateSource
JenaValve Technology, Inc.PMA supplementOct 7, 2026FDA
JenaValve Technology, Inc.PMA supplementOct 13, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

JenaValve Technology, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Cromwell, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records